​

·         Yun, J., E. Mullarky, C. Lu, K. N. Bosch, A. Kavalier, K. Rivera, J. Roper, Chio, II, E. G. Giannopoulou, C. Rago, A. Muley, J. M. Asara, J. Paik, O. Elemento, Z. Chen, D. J. Pappin, L. E. Dow, N. Papadopoulos, S. S. Gross and L. C. Cantley (2015). "Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH." Science. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. - PubMed - NCBI

 

​

 

•          Vollbracht, C., B. Schneider, et al. (2011). "Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany." In Vivo 25(6): 983-990.

• Vollbracht, Schneider et al. 2011)

 

•          Harris, H.R., N. Orsini, and A. Wolk, Vitamin C and survival among women with breast cancer: a meta-analysis. Eur J Cancer, 2014. 50(7): p. 1223-31.Vitamin C and survival among women with breast cancer: a meta-analysis. - PubMed - NCBI

 

•          Guerriero, E., et al., Vitamin C effect on mitoxantrone-induced cytotoxicity in human breast cancer cell lines. PLoS One, 2014. 9(12): p. e115287.Vitamin C effect on mitoxantrone-induced cytotoxicity in human breast cancer cell lines. - PubMed - NCBI

 

•          Cha, J., M. W. Roomi, et al. (2013). "Ascorbate supplementation inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in vitamin C-deficient mice." Int J Oncol 42(1): 55-64. (Cha, Roomi et al. 2013)

• ​

 

http://iv.iiarjournals.org/content/25/6/983.full.pdf+html

​

​

•          Welsh, J. L., B. A. Wagner, et al. (2013). "Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial." Cancer Chemother Pharmacol 71(3): 765-775.

Pharmacological Ascorbate with Gemcitabine for the Control of Metastatic and Node-Positive Pancreatic Cancer (PACMAN): Results from a Phase I Clinical Trial

 

 

•          Monti, D.A., et al., Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One, 2012. 7(1): p. e29794.

Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer

 

•          Espey, M. G., P. Chen, et al. (2011). "Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer." Free Radic Biol Med 50(11): 1610-1619.

• Espey, Chen et al. 2011)

• ​

 

•          Du, J., S. M. Martin, et al. (2010). "Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer." Clin Cancer Res 16(2): 509-520.

• Du, Martin et al. 2010)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807999/pdf/nihms157377.pdf

​

​

•          Chen, M.F., et al., Vitamin C protects against cisplatin-induced nephrotoxicity and damage without reducing its effectiveness in C57BL/6 mice xenografted with Lewis lung carcinoma. Nutr Cancer, 2014. 66(7): p. 1085-91. Vitamin C protects against cisplatin-induced nephrotoxicity and damage without reducing its effectiveness in C57BL/6 mice xenografted with Lewis lu... - PubMed - NCBI

 

​

•          Fromberg, A., D. Gutsch, et al. (2011). "Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs." Cancer Chemother Pharmacol 67(5): 1157-1166.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082037/pdf/280_2010_Article_1418.pdf

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​